This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Apogepha Arzneimittel Gmbh. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: The Innovations of Dirk Pamperin
Introduction
Dirk Pamperin is a notable inventor based in Dresden, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms. His innovative work focuses on enhancing the delivery and effectiveness of active ingredients in medication.
Latest Patents
Dirk Pamperin holds a patent for an oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient. This patent describes the production of oral pharmaceutical compositions containing propiverine in amounts ranging from 4 mg to 60 mg. The compositions are designed to provide a prolonged release of the active agent, utilizing a blend of the active ingredient and one or more acidic substances with a pK value of less than 6.65. These formulations are either coated with a retarding layer or embedded in a matrix that may also be coated with additional retarding layers.
Career Highlights
Dirk Pamperin is associated with Apogepha Arzneimittel GmbH, where he applies his expertise in pharmaceutical innovations. His work has contributed to advancements in drug formulation and delivery systems, enhancing patient outcomes through improved medication efficacy.
Collaborations
Dirk has collaborated with notable colleagues such as Thomas Gramatte and Peter Gruber. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the pharmaceutical field.
Conclusion
Dirk Pamperin's contributions to pharmaceutical innovations, particularly in oral dosage forms, highlight his commitment to improving medication delivery systems. His work continues to influence the industry and enhance patient care through effective drug formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile